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determ$d rejection and ac&!erated graft vas- 
culopathy, the latter with a prevalence of approximately 4046 
to 50% at 5 years (1). The mechanisms leading to transplant 
vasculopathy are still unclear. The morphology of transplant 
vasculopathy shows distinct diEerences from that of athero- 
sclerotic lesions in patients with ~mwuy artery disease (2). 
suggesting di&cnt pathologic mechanisms. Nevertheless. 
the consequences of transplant vasculopathy and atheroscle- 
rosis are similar, both leading to coronary artery obstruction 
and myoeardial schemia. 
Recently, Fish et al. (3) demonstrated that in the majority 
of patients after heart traasplantatioo, C nnJary artnies fail 
to dilate or display pwadoxic vascumstri&n in response to 
intracoronary cetykholine. In contrast, as demwsbated by
the same group (4). intracomnary acetylclmlim dilates UK 
arteries in normal patients with no signs of arteriosclerosis 
(as judged by angiognphy); these investigdtors therefore 
suggested that endothelii dystimction is pasent in beat 
transplant patients and may have some causal relation to the 
development of transplant vasculopathy. Endotbelial cells 
are known to modulate vascular tone by the release of 
various factors, especially endotbeliumderived relaxing fat- 
tar (EDRF) (5). In patients .vith coronary artery disease, 
vascdilation mediated bythe release of EDRF is markedly 
impaired (6,7). This phenomenon may precede the develop 
ment of angiographically visible atherosclerotic les ons (8) 
and may contribute o the pathogen& of vascular comply- 
cakm.5 inpatients with atherosclerosis (9).
Acetylchaline, often applied as an endothelium- 
dependent dilator. was shown to exhibit dual etfects 011 
vascular tone: relaxation due to the release of EDRF and 
constriction due to direct smooth muscle e5ects. Thus, 
acetylcholine may not be the best substance to test EDRF 
release in viva. I” fact, several studies (IO-14) on the e5ect 
of intracoronary acctylcholioe repotted vasoconstrlction as 
the principal response, irrespective of the presence or ab- 
se”ce. of angiographic :igns of atherosclemsis. I” agreement 
with the in viva studies, acetylcholine also produced vasa- 
constriction in isolated human coronary arteries that ap- 
peared histologically free of atherosclerotic lesions (1s). 
Substance P appears to be more selective than acetylcho- 
tine in mtiulating vascular tone by the release of EDRF. In 
vitro relaxation induced by substance P in human coronary 
arteries is strongly dcpcndent on the presence of intact 
endothelial cells; furthermore, substance P does not directly 
affect coronary smooth muscle tone (6.7.15). In viva, intm 
coronary substance P induced dilation of epicardial caronaty 
arteries as well as a reduction in coronary vascular resis- 
tance (16). Recently, substance P has also been shown to 
dilate epicardial coronary arteries in cardiac transplant pa. 
tients with angiogmphically “nomul” coro”ary arteries 
(iii. 
I” the present study, we reevaluated the hypothesis that 
transplant vasculopathy in heart transplant patients is ass”- 
ciated with endothelial dysfunction (that is, impaired EDRF- 
mediated vasodilation). However, in e”“trast to pk?vi~~s 
studies, we used substance P, nitmglycerin and papaverine 
to test endothelial and smooth muscle function in heart 
tramplant patients with and without U’aosplaot vascolopa- 
thy. Endothelial function was determined by measuring 
changes in corotwy Row velocity and epicardial corooary 
artery diameter during cardiac catheterization. 
Methods 
SIudy pslhta (TabI+ 1). Twenty-three patients undergo- 
ing routine diagnostic cardiac catheterization were studied 
39.9 k 4.1 months (mean 1 SEM) after heart ~ansplanta- 
tion. Heart transplantation was performed for ischemic heart 
disease in 6 patients, for idiopathic cardiomyopathy in I6 
and for a malignant cardiac tumor in I patient. Patients were 
classified into patients with (n = 8) and without (n = 15) 
transplant vascalopathy on the basis of the diagnostic corn-- 
nary aogiogmms that were independently reviewed by two 
cardiologists. Traas~lattt varculopathy was defined accord- 
ing to Gao et al. (18). Type A consists of focal eccentric 
lumen “arrowi”g or obstruction involving the proximal epi- 
cardial vessels.~Type B describes normal pro&il v&Is 
with di5use narrowing of medium-sized a”d distal vessels, 
including sudden cutoff or smwth cylhtdtic tapering of the 
arteries involved. Type C is characterized by irregular 
proximal and diffusely diseased distal vessels. The lesions in 
four of the eight patients with tnnsplant vascolopathy con- 
sisted of focal eccentric lumen narrowing of the right con- 
nary arta-~ 01 = 2). left circumflex artery tn = 1) and the 
midportio~ of the left anterior descending artery (n = I, 
stenosis <SO%): in the remaininn four oatients with trans- 
plant vascolopathy, diiuse lesions wei seen in the right 
(n = 1) and the left cirettmflex (n = 3) coronary artery. At 
the time of routine annual cardiac catheterization, all pa- 
tients were without evidence of acute cardiac rejection in 
endomyocardial biopsy samples. Patients remained on their 
immunosuppressive medication (cyclosporioe, steroids. aza- 
tb~oprine). Additional cardiac medication (aogiotensin- 
conwtiogeozyme inhibitors) was similar in both groups and 
was continued. No patient was taking nitrates or calcium 
antagonists. 
Shnly desigo. Written informed consent was obtained 
from all patients before cardiac catheterization in actor- 
dance with guidelines of our local Ethical Committee. Diag- 
nostic right and left heart catheterization. including right 
veotricolar endomyocardial biopsy and coronary aogiogra- 
phy, was performed by standard techniques. An 8F Gemini 
catheter with side hales was placed into the midportion of 
the corawy vettow sinus just distal to the anterior inter- 
ventricular vein. Before completion of coronary aogiogm- 
phy, an addltiooal 5,OOiJ U of intracom~ hepati was 
given and an 8F goidiog catheter (MaUinckrodt) was posi- 
tioned in the ostium of the left coronary artery. A 2&MHz 
pulsed Doppler infusion catheter (3F. Millar Instruments) 
-&s adw&d over a 0.012~in. (0.03 cm) guide wire through 
the guiding catheter into the proximal segment of the left 
aotaior deseendhtg artery. The Doppler catheter was care- 
ftdlv wsitioned to obtaio a stable Row velocitv sieoal. The 
g&wire was then withdrawn and the goid& catheter tip 
removed from the coroimry ostium during flow measure- 
ments. The range-gate control was then adjusted to optimize 
the audio flow velocity signal nod the phasic flow velocity 
waveform; the range-gate control was not changed thereaf- 
ter. This technique has been previously shown to allow 
continuous reliable measurements of blood Row velocity 
(8,wO). 
Five minutes after control angiography, serial b&s in- 
jections (1 ml) of substance P (20 pmol dissolved in saline 
solution), oitrogly&n (0.1 mg diluted in saline solution), 
sallw solution ~o&ol and pap&tine (8 tog diluted in saline 
solution) were administered in bmin intervals through the 
cetttral lumen of the Doppler catheter. The time of bolos 
ioiection lasted <S s 113). and 50 s after each intervention 
h&d injections of n&o& contrast material for coronary 
aogiogmphy (Ulhavist, Scheriog AC) were repeated. An- 
giography was pafomwd after velocity measurements to 
avoid the contusing effect of contrast medium on coronary 
llow. Thmoghoot the bolos injections. heart rate, blood 
presswe and phasic and mean coronary llow velocities were 
continuously recorded. Bolus injections were well tolerated 
by all patients. The time interval of approximately 5 min 
between each intervetttioo appeared to be sticient to allow 
hemodynamic equi’ibratkm to baseline values, as judged by 
blood pressure and coronary blood Row velocity. In six 
patients with anti~bicallv oorroal comoaw arteries. 
additional pham&&& intekerdions were &formed 10 
to I5 min before the serial bolus ioiections. In these oatients. 
intracorooary saline so%ion f&owed by sub&ce P 
(20 pmollmin) was ittlttsed throogh the Doppler catheter 
lumen for 2 min at an infusion rate of I ml&x. Bload 
samples (2.7 ml drawn in 3.6 mo&liter of EDTA and 
I mmollliter of M&B 22,948) were collected from the com- 
nary sinus at 0,30,60.9u and 120 s do&g the infusion of 
saline solution and sobstatxe P. An additional blood sample 
was obtained 30 s after stopping the iofosioo. These blood 
samples were used to meawe platelet cyclic guaoosioe 
5’.monophosphate (GhfP) content. 
Quantitative mroaaq an P. Coronary angiogra- 
phy was performed with a simoltaoeous biplane LABC 
system (Phillips). The left anterior desceodii artery was 
positioned near the isocenter. Biplaoe 3.5~mm c&an.+ 
mams were recorded at a rate of 25 frames/s. End-diastolic 
angiograms were evaluated by a computerassisted edge 
detection system (Cardiovascular Aogiography Analysis 
System). as described previously (21). Comoary artery 
diameter was calibrated on the cioe frame by comparison of 
the tip of the coronary catheter with a precision caliper 
immediately alter aogtogmpby (21). Selection of optimal cioe 
frames and corooary segments was performed by an ape- 
rienced cardiologist without knowledge of the patients’ drug 
regimen and clinical data. For each intervention, three 
wments II to 2.cm oonbmnchiog wmentl were mdvzed: 
one s gment of the circumlkx artery for reference purposes 
and one wanem each omxlmal and distal to the tip of the 
Doppler cafheter. The $wimal segment was oat ex&ed to 
the iqjected substances and served to determine flow- 
dependent changes in coronary artery diameter. The distal 
segment was exposed to the substances iojected through the 
lumen of the Doppler catheter. Vessels were assumed to 
have a circular cross section. and area was calculated as 
s?. 
Measorement ofphtdct cyclic GMJ c&at. Blood sam- 
ples drawn from the coronary veooos sinus were centrifoged 
(200 g, 10 min. 4T”c). Platelet-rich plasma was collected and 
recentrifuged (400 g, 10 min. 4°C). The supematants were 
discarded and pellets were resuspended in 0.5 ml ofice-cold 
ethanol (7036 in distilled water) and agitated for I min. After 
centrifogatian (2,OIX.l g, 10 mio, 4’0, supematants were 
dried overnight under vacootn. Pellets were dissolved in 
sodium acetate (50 mmol/liter), and the cyclic GMP content 
of the samples was measured by radioimmunoassay, as 
described previously (22). 
hfaterlal. Dmgs were obtained from the followiog corn- 
pa&s: Substance P from Clihtia, Basel, Switzerland: ni- 
troglycerin (Pertinganit) from Schwarz Pharma, Monheim. 
Germany; ppaverine @wcmn) From Kxlspharma, Karls- 
stance (20 pmol) and vehicle 
aride 1NaClP on blood ROW 
Figare 1. Effect of intracoronary sub 
(0; saline solution, O.% sodium chl 
velocity (at, epicardial cornnary artery diameter (I# and mwm 
arterial pressure (c) in patients atIer heart transplantation. Sub 
stance P wea injected through a Doppler catheter that was placed 
into the midponion of the left anterior dcrccnding artery (LAD). 
Mean arterial pressure and coronary Row velocity were measured 
More and 10 to 50 s after substance P injection. Conmay artery 
diameter (proximal IRox.1 and distal to the tip of the Do&r 
carheter; circumtlex artery as a reference [act] sepnt) was 
measured by quantitative angiogmphy 50 s at7cr substance P injec- 
tion. lntracoronary injection of saline solution had no etkct an 
coronary artery diameter. Experiments WR performed in I5 pa- 
tients without mgiographic signs c4 transplant vascutopathy (TVP 
neg) and 8 patients with angiogra~hically proved tmnsplmt vascu- 
l-apathy WP pas). Values are man value + SEM: mttrkka denote 
sigttificam ditTerettces between patients with and without mgio 
graphic evidence of transplant varculopathy. 
ruhe, Germany. The M&B 22,948 was a gift from Rhanc- 
Poulenc Row Ltd., Dagettham, England. 
Stalistl~~. All data are expressed as a mean value *SEM. 
Diierences between the patients with and without ransplant 
vasculopathy were evaluated by analysis of variance 
(ANOVA). P!atelet cyclic GMP cmttents at different time 
points were evaluated with an analysis of variance, followed 
by the Fisher protected least significant difference test for 
comparison of d&rent means. Statistical significance was 
assumed at the 0.05 probability level. 
Realllts 
Eight of 23 patients showed angiographic evidence of 
transplant vasculopathy (Table I). Patients with and without 
transplant vasculopathy did not dilfer with regard to the 
underlying heart disease before heart transplantation, nutn- 
b-z of treated rejection peticds, ischemic time or plasma 
cholesterol evels. 
SuhstamxP@igig. 1). Injection ofvehicle (saline solution) 
through the Doppler catheter lumen caused a transient 
minimal (16%) increase in left anterior descending artery 
FIgme 2. Effect of idracomnary nitroglycerin (0.1 mg) on blood 
Row velocity (d, epicardial cornnary artery diameter(b) .wd mean 
arterial pressure (c) in patients after heart transplmlztion. Nitro- 
glycerin was injected through a Doppler catheter that was placed 
into the midportion of the left anterior descending anery (LAD). 
Mean arterial pressure and coronary Row velocity WR measured 
before and 10 to 50 s after nitroglycerin i jsction. Cornnary artery 
diameter@ximalanddistalto the tipoftheLkpplercatheter)was 
measured H) s after nitmglycerin ijcction by quantitative aagiog- 
r&y. Experiments were perforated in I5 patients without angic- 
graphic signs of transplant vasculopathy GW negl and 8 patients 
with a&graphically proved transplant vasculopathy (TVP ps). 
Values are mean value + SEM; aderivk denotes si&ftcant d&r. 
mccs between pattents with and without angiographic evidence of 
transplant vasculopathy. 
blood flow velocity, which was almost nortaalized to base- 
line within IS s after bolus injection (Fig. la). In patients 
without evidence of tmnsolant vasculcmathv. substance P 
maximally increased coronary Row v&& by appmxi- 
matelv 117%. with a oeak increase IO to 20 s after a b&s 
inject& that lasted kr 40 s (Fig. la). In patients with 
evidence of transplant vascttlopatby, the substance P- 
induced increase in peak to baseline ikw velocity was 
significantly impaired (117 * 17% vs. 38 + 12%, p < 0.01) 
(Fig. la). Epicardial coronary artery diameter meawed 
distal to the tip of the Doppler catheter increased in reswnse 
to sub&ace P by 11.7 _j.O% in patients without tratt~plant 
vasculopathy and by 5.3 + 3.8% in tmtients with ttansnlattt 
diameter measured proximal to ihe tip of :he 
catheter increased after substance P iniection bv 4.5 * 3.1% 
and 0.1 k l.%, respectively, in pi& with&t and with 
trattsplant vasculopathy (p = NSl (Fig. lb). The refwance 
segment (circumflex cwxary mar/) showed almost no 
change in diameter after substance P it&c.tion in both groups 
(Fig. lb). Beginning 20 s after ‘b&s injection (Fig. Ic), 
intt’acoronary substance P injection slightly reduced mean 
arterial pressure in both groups. 
NltmgIyczti @lg. 2). In both patient groups, nitmgIyc- 
erin produced a biphasic response on cormtary flow velocity: 
first a short-lasting increase, then a decrease ia peak to 
FIgme 3. Effect of intracnronary papaverine (8 mg) on bload Row 
velocity (a). epicardial coronary a’tery diameter tb) and mean 
arterial pressure 0 in patients after heart ransptamation. Papaver- 
ine was injected through a Doppler catheter that was placed into the 
midportion of the left anterior descending artery (LAD). Mean 
arterial pressure and coronary flow velc-zity were measured before 
and 10 to 50 s alter papave+ injection. Comnary artery diameter 
(proximalanddistal to the tipoftheDoppler catheter) was measured 
50 s after papaverine injection by quantitative anngiograpby. Exper- 
iments were performed in IS patients without angiographic signs of 
transplant vaseutapathy (TVP nep) and 8 padcms with angiegraph- 
ically proved transplant vasculopatby l,TW pas). Values are mean 
value + SEM: ad&k denotes si~iiicanr ditlerences between 
patients with and without an&graphic evidence of transplant vas- 
cldopa*y. 
baseline Row (Fig. 2a). This short-lasting increase in peak to 
baseline flow was somewhat less in patients with than in 
patients without evidence of transplant vasalopathy when 
evaluated 10 s after bolos injection (80 5 22% vs. ij f 5%. 
p < 0.05) (Fii. 2a). Epicardial coronary artery diameter 
meawed distal to the tip of the Doppler catheter increased 
in response to nitroglycerin by 16.3 + 4.2% in patients 
without and 14.1 f 2.6% in patients with transplant vas- 
culopathy (p = NS) (Fig. 2b). Ep&dial coronary diameter 
measured proximal to the tip of the Doppler catheter in- 
creased r&r nitmglycerin injection by 6.5 ? 2.1% and by 
2.0 f 2.8%. respectively, in patients without and with 
transplant vasculopatby (p = NS) (Fig. 2b). Intracorona~ 
nitroglycerin injection reduced mean arterial pressure to a 
similar extent in bath gmops (Fig. 2~). 
Papaveriw Qig. 3). lo both groups of patients, intracor- 
onary papaverinc produced a pronounced increase in cork 
nary ilow velocity by approximately XX?%, which was at its 
maximum at 30 s after bolos injection (Fig. 3~). This increase 
in peak to baseline flow was of similar magnitude in patients 
with and without evidence of transplant vasculopatby (304 f 
3% vs. 336 + 46%. respectively, p = NS) (Fig. 3a). 
Epicardial coronary diameter measured distal to the tip of 
the Doppler catheter increased in response to papaverine by 
18.2 + 4.0% in patients without and 16.5 ? 3.0% in patients 
with transplant vasculopathy (p = NS) (Fig. 3b). Epicardial 
Figure 4. Plot of the percent change in platelet cyclic guarmsinc 
I’-monuphorphate (tiMPI mntent of Mood samples obtained from 
the coronary weneus inus during intracomezy i&r&o of sub 
srance P 00 pmoVmin for 2 min). Expedrnenrs were performed in 
six patients m* angiographicatty rmmut coronary aneries after 
heart trrmsplantalirm (no evidence of tranqtaet vaseulopathyl. 
Basal cyclic GtdPcontent wasO.ZJ r O.O78pmovSamp!e. Subs&a 
P infusion caused significant increases in platelet cyclic GMP 
content as observed 8160 and ‘w) s atIer the srat of infusion (*p < 
0.05 vs. basal wlue:,. Thirty seconds tier sroppis d,e i,,fusion, 
platelet cycbc GMP content had already dcctimd to basal kvets. 
Infusion of vehicle (settee sotution) did not significatty affect 
platelet cyclic GYP content. Values are mean value 2 SEM. 
coronarv diameter measured oroximal to the tie of the 
Dapple; catheter increased r&r papaverine injection by 
13.5 + 3.8% and 0.4 + 3.9% in patients without and with 
transplant vasculopathy, respectively (p < 0.01) (Fig. 3b). 
Intracoronary papaverinc injection slightly reduced mean 
arterial pressure to a similar extent in both groups (Fig. 29. 
sut6lMce P.ioduced iocreaw iUplet&tC@iCGMPcOn- 
tent (pig. 4). Durine intracomnaw infusion of substance Pin 
patiAt;&out evidence oft&plant vasculopati~y, plate- 
let cyclic GMP content in blood samples from the coronary 
venous sinus increased by approximately f&% compared 
with basal levels (measured in samples obtained immediately 
before starting substance P infusion). Within Xl s after the 
end of infusion, cyclic GMP content decreased almost to 
baselinr values. Intracoronary infusion of vehicle (saline 
solution) did not a&t platelet cyclic GMP Eootent. Also, in 
vitro incubation of whole bloat with substance P (0.1 to 
IO nmollliter) in the presence of the cyclic GMP pbospho- 
diesterase inhibitor M&B 22,948 (I mmol/litcr) did not 
increase platelet cyclic CMP content (n = 3; data not 
shown). 
Discussion 
Several observations suggest that mechanisms of trans- 
plant vasculopathy are diicrent from those of common 
atherosclerosis. Transplant vawlopathy aifects transplant 
recipients without typical cardiovascular isk factors whose 
own heat? had no cornnary artery disease (2). Several 
pathogenic mechanisms for txaospkmt vascolopatby have 
been proposed (1). including endothelial damage tbmugb 
cytomcgalovirus infection (23), immunologic incompatibility 
between donor and recipient (24) and antibody-mediated 
rejections (25). 
fn this study, we tested the hypothesis that endotheliel 
damage is present in patients with transplant vascolopathy. 
Endothelial function was tested by measuring vascular re- 
sponses to intracoronary substance P, an endothelium- 
dependent vasodilator, and changes io blood t%w after 
intracoronary administration of papawine. Our results 
show that the vasodilator response of the microvasculature 
to intracorooary substance P is signiticaotly impaired in 
patients witb coronary&t vascolopathy compared with tbe 
response in transplant patients with angiogrephically normal 
coronery arteries. In addition, flow-mediated dilation of 
epicardial co*ooary arteries in response to papawine ap- 
pears to be abolished in patients with transplaa vawlopa- 
thy. III cootrest, vasodilation of epicardial arieries in re- 
sponse to intrecoronwy nitroglycerin and an increase in 
coronary flow velocity in response to intracorottary papa”- 
wine were similar in transplant patients with and without 
transplant vascolopathy. These results suggest that trans- 
plant vasctiopatby in transplant patients is associated with 
endothelial dysfunction (that is, impaired EDRF-mediated 
vasodilation). 
Limitations of study. Substance P is a neuropeptide found 
in sensory neurons of the peripheral nervous system, vagus, 
some sympathetic ganglia and the perivasculer nerves of 
~smell arterioles in the human heart (17.26). In isolated 
human coronary arteries, substance P is a potent and specific 
stimulator of EDRF release (6,7,15,27,28). In contrast to 
acetylcholine. substance P has no direct effects on coronarv 
smooth muscle tone (6.7.14.28). Thus, it may be mori 
suitable than aatvlcholine for studvina EDRF-mediated 
vascu!ar espnnees~in the human coronery circulation. Con- 
versely, dilator responses to substance Pin human epicardial 
coronary arteries in vitro are known to be transient because 
of a tachyphylaxis phenomenon (?,a. Even one concentra- 
tion of sub&rice P causes tachyphylaxis, at least under in 
vitro conditions (7,lS). It is unknown whether this phcnom- 
enon is restricted to large epicardial arteries or involves both 
large and resistance coronary arteries. Because of this 
phenomenon, we used bolos injections of substance P in- 
stead of infusions in tbc oresent studv. This studv desinn 
may have certain liitatio~s. Although quaotitativ~ amgioi- 
raphy was performed shortly (50 s) after bolos injection, 
changes in coronary diameter migbt not be measured at 
steady state conditions. This limitation appears to be of 
minor importance for relatively long-acting substawes (for 
example, nitroglycerin and papaverine). In fact, quantitative 
angiogmphy revealed substantial changes in coronary artery 
diameter in response to nitroglycerin and papaverlne even 
50 s after the start of the bolos injection that were of similar 
magnitude to those in other studies using intreconmary 
infusion protocols (13,16,17.29). This limitation, however, 
may have certain implications for short-acting drugs such as 
substance P. At the time of quantitative angiography, sub- 
stance P-induced increases in coronary flow velocity were 
almost normalized to baseline values. Thus. measurements 
50 s after bolus injection may slightly underestimate the 
vasodilator effects of substance P on large epicardial atter- 
ies. It is reasonable to assume that this underestimation ot 
the vasodilator effect of substance P will occur in patients 
with or without transplant vasculopathy. Thus. this ootential 
systematic error is not likely to int&ere with tk main 
emphasis of tbe present study to compare vasodilator re- 
sponses between both group of patients. 
PI&let cyclk GMP moteot. In six patients without evi- 
dence of traosolant vasculowtb~, we also tested the hvwtb- 
esis that intra~oronaty s&st&e P does stimulate iie re- 
lease of EDRF. which is known to increase cvclic GMP 
content in plat~iets in vitro, thereby inhibiting &&let ag- 
gregation (30-32). In agreement with these in vitro observa- 
tions, stimslation of EDRF has also been reported (33) to 
increase cyclic GMP levels in washed platelets during pas- 
sage through the coronarv vascular bed of isolated rabbit 
he&s. A similar phenome&n could be demonstrated in the 
present study. During infusion of substance F, cyclic GMP 
content in the plasma-rich fraction of blood samples drawn 
from the coronary sinus increa.sed approximately 60%. In- 
cubation of whole blood with substance P did not affect 
platelet cyclic GMP content. Furthermore, infusion of vebi- 
clc (saline solution) had no effect on platelet cyclic GMP 
content. These rreliminerv findinns are consistent with tbe 
hypothesis that~intmcorohery substance P stimulates tbe 
release of EDRF and that lumbxdIv released EDRF in- 
creases the cyclic GMP contcttt in &dating platelets in 
humans. Although it was not the porpasc of the present 
study to cbaracterlze this phenomenon for&r, this obser- 
vation might contribute to oar undcrstaodlng of the ffects of 
substance P in patients without evidence of hansobmt vas- 
colopathy and ihe results observed in patients &th such 
evidence. In addition. it ndebt form the basis for a biochem- 
ical test using circulaiing platelets as an indict indicator of 
endothelial ftmction in patients with transplant vascolopatby 
or coronary artay disease. 
comparlseo wilb Pmiooa shIdk& Crossmao et al. (16) 
eter and a significant in the corona& blood 
oxygen saturation in response to intracoronary substance P 
in 13 patients with a&graphically ttormal coronary arter- 
ies. These results suggest that intracoronary substance P 
dilates both large arteries as well as resistance vessels. 
Kushwaba et rd. WI demonstrated in 12 heart trawlant 
patients without transplant vasculopatby a signific&t in- 
crease in epicardial coronary artery diameter that was sim- 
ilar in magnitude to that achieved with isosorbide dbdtrate. 
These results suggest that endothelial function as assessed 
by vascular responses to substance P is principally pm- 
served in heart twtsplard recipients with aogiographically 
norroal coronary arterie. In agreement, our study also 
demonstrated a substance P-induced increase in epicardial 
coronary artery diameter and a reduction in coronary vas- 
cular resistance io patients without bansplant vascolopathy, 
suggesting that substance P dilates both large and small 
(resistance) coronary arteries. Because intracoronary sub- 
stance P increased coronary flow, changes in epicardial 
coronary artery diameter may be mediated indirectly by 
increased flow, as well as through direct effects on dte vessel 
wall. In the present study, the distal but not the proximal 
segment of the I& anteti& descending artery was.exposed 
to drugs. Thus, changes in diameter of this proximal segment 
can be assumed to be Row mediated (34). In our study, in 
contrast to the distal left anterior descending artery segment, 
the proximal diameter of this vessel did not increese signif- 
icantly in response to substaoce P. although coronary blood 
Row vehxitv increased bv about twofold in oatients without 
evidence oi transplant v&ulopathy. This hnding suggests 
that the increase in the diameter of the distal coronary 
segment in response to substance P is mainly drug mediated 
and not flow dependent. In coutra~, the increase in coronary 
flow velocity in response to substance P probably was not 
su6icient to cause flow-dependent dilation. In comparison. 
intmcomnary papaverlne in the same patients increased 
corouaty flow velocity by about fourfold and this led to a 
signiticard (approximately 18%) increase in proximal core- 
nary artery diameter. 
In patients with evidence of transplant vasculopathy, 
dilatiat of the distal kft anlerior descending urtery Segment 
in response to substance P was attenuated compared with 
that in patients without such evidence. Furthermore, peak to 
baseline Sow velocity in response to substance P was 
signiicatttIy reduced in patients with transplaut vasculopa- 
thy. This reduced responsiveness of epicardial and resis- 
tattce corooay arteries to substance P was not due to a 
getteral @a&m of the relaxing mechanisms. In the same 
patients, maximal epicardial coronary dilation in response to 
nitroglycerin and maximal reduction in regional left anterior 
descending artery resistance in response to papaveriue were 
preserved. There results suggest that selective vascular 
responses to substance P are impaired in patients with 
transplant vasculopathy. most likely as a result of the 
reduced release of EDRF. The present study cattoot exclude 
the possibility that iuttacoronary substance P induced the 
release of endotheliumderived vasoconstricton in patients 
with transplant vasculopathy. This corelease of vasocon- 
stricton would also result in impaired vasodilation in re- 
sponse to substance P. This possibility. however, appears to 
lx tutlikely because substance Pdoes not elicit vasocons~ric- 
tiou lu vitro (28) or in viva atIer inhibition of EDRF release 
with L-arginhte analogues (35). 
Intracomnary nitroglycerin injections produced a small 
transient increase in blood flow velocity that was somewhat 
less in patients with evidence of transplant vasculopathy 
campared with control patients. The rahauism of this 
hausient response to intracoronary nitroglycerin is not 
known. Thus, it remains unclear whether this impaired effect 
of iutracomutuy uitroglyceriu on blood tlow velocity in 
patients with transplant vusculopathy is related to adothe’ 
lid dysfunction. 
Ahdiihed Row. .ASWMlmajor 
finding of the present study is that flow-n&i&d dilation of 
epicardial coronary arteries is abolished in patients with 
evidence of tmnsolant vasctdowthv. Mecbauisms of ftow- 
mediited vasodil&iou are cont&x~acd involve opening of 
ion channels and release of humoral v asocQustrlctoR and 
vasodilators (36). Flow-mediated diitioo of larger arteries 
appears to be dependent on intact endotbelial cells and 
probably involves the release of EDRF (37.3-S). Thus, the 
lack of Row-mediated vas@dilation of epicardial coronary 
arteries in patients with evideoce oftraus&ot vascukmathv 
would be consistent with the hypothe& that t&p&t 
vasculo~athv is associated with end&&d dvsfunction (that 
is, red&d r&ase of EDRF). Similar to the &eseut tir&gs 
in patients with evidence of tt-attsp~;nt vasctdopathy, im- 
paired Row-dependent relaxation has been described in 
&ems with &x!ary artery disease. Whereas the peak 
increases in blood Bow in reswnse to adenosine (391 w 
papaverine (40) were similar in patients with augiographi- 
ally normal or diseased coronary arlaies, dilation of a 
proximal corouury artery segment hat had been exposed to 
increased flow but not to the drugs was ktuully abolished in 
patients with atherosclerosis. The precise mechanism of 
impaired Row-mediated ilation in patients with coronary 
artery disease is u&nown. 
Impaired vascular responsiveness to introcoronary sub- 
stance P and loss of flow-induced va&ilatioo of epicardial 
human coronary arteries might be sipns of ow oathorzetdc 
mechanism in &ieuts with-tramp&t vasctdop&y. Both 
ohenomena could be related to imoaired release of EDRF. It 
remains unclear why certain pa&uts elicit these vascular 
abnormalities after heart transplantation. At present, a pn- 
ma-y immunologic *tinudus, iucludii chronic regional im- 
mune respunses and stimulation of itdlammatory cells, is the 
most likely explanation for the developmerd of transplant 
vasculopathy (I). The link betweeo immune responses! 
stimulation of inflammatory cells and the hypothetized im- 
paired EDRF release in patients with transplant vasctdopa- 
thy is unknown; one might speculate that this phenomenon is 
related to the “oxidative stress” secondary to inflammatory 
cells, as was recently suggested in an auimal model of 
atherosclerosis (41,42). 
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